

Docket No.: 62386-043

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of	:	Customer Number: 20277
	:	
WAYNE D. COMPER	:	Confirmation Number: To be assigned
	:	
Serial No.: Continuation of Application No. 09/893,346	:	Group Art Unit: To be assigned
	:	
Filed: November 26, 2003	:	Examiner: To be assigned
	:	
For: METHOD FOR KIDNEY DISEASE TREATMENT BY DRUG INTERVENTION		

INFORMATION DISCLOSURE STATEMENT

Mail Stop NEW APPLICATIONS
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached form PTO-1449. It is respectfully requested that the references be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.

The references were cited by or submitted to the U.S. Patent and Trademark Office in parent application Serial No. 09/893,346 , filed June 28, 2001 , which is relied upon for an

Serial No.: Continuation of
Application No. 09/893,346

earlier filing date under 35 USC 120. Thus, copies of these references are not attached. 37 CFR
1.98(d).

Please charge any shortage in fees due in connection with the filing of this paper, including
extension of time fees, to Deposit Account 500417 and please credit any excess fees to such deposit
account.

Respectfully submitted,

MCDERMOTT, WILL & EMERY



Thomas A. Haag
Registration No. 47,621

600 13th Street, N.W.
Washington, DC 20005-3096
(202) 756-8000 TAH:BD
Facsimile: (202) 756-8087
Date: November 26, 2003

WDC99 846788-1.062386.0043

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)				ATTY. DOCKET NO. 62386-043		SERIAL NO. Continuation of Serial No. 09/893,346	
				APPLICANT Wayn D. COMPER			
				FILING DATE November 26, 2003		GROUP To be assigned	
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
	5,246,835	9/21/1993	Suzuki et al.				
	5,534,431	7/9/96	McDonald				
	5,654,158	8/5/97	McDonald				
	5,908,925	6/1/1999	Chen et al.				
FOREIGN PATENT DOCUMENTS							
						Yes	No
	514,928 A2	11/25/92	EP				
	4,336,498 A1	4/27/95	Germany				
	6082446	3/22/94	Japan				
	WO 00/37944	9/29/2000	WIPO (PCT/IB99/02029)				
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	<i>Proceedings of the Society for Experimental Biology and Medicine</i> , December 1997. 216(3):41423. Sabatino, B. and Van Liew, J.B., The renal handling of IgG in the aging rate and in experimental kidney disease.						
	<i>Kidney International</i> , February 1991. 39(2):307-11. Ohta, K. et al., Urinary excretion of endothelin-1 in normal subjects and patients with renal disease.						
	<i>Journal of Chromatography</i> , 29 July 1988. 429:3150-44. Weber, M.H., Urinary protein analysis.						
	<i>Clinical Nephrology</i> , March 1979, 11(3): 140-41. Blainey, J.D. and Terry, J.M., Urinary fibrinogen degradation products and differential protein clearances in renal disease.						
	<i>British Medical Journal</i> , 22 February 1975. 1(5955): 419-22. Hall, C.L. et al., Urinary fibrin-fibrinogen degradation products in nephrotic syndrome.						
	"Protein Degradation During Renal Passage in Normal Kidneys is Inhibited in Experimental Albuminuria", by Osicka et al., <i>Clinical Science</i> (1997) Vol. 93, pp. 65-72.						
	"Fractional Clearance of Albumin is Influenced by its Degradation During Renal Passage", by Osicka et al., <i>Clinical Science</i> (1997) Vol. 93, pp. 557-564.						
EXAMINER				DATE CONSIDERED			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)			ATTY. DOCKET NO. 62386-043		SERIAL NO. Continuation of Serial No. 09/893,346	
			APPLICANT Wayn D. COMPER			
			FILING DATE November 26, 2003		GROUP To be assigned	
U.S. PATENT DOCUMENTS						
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
FOREIGN PATENT DOCUMENTS						
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation
						Yes No
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)						
	"Alterations in Renal Degradation of Albumin in Early Experimental Diabetes in the Rat: A New Factor in the Mechanism of Albuminuria" by Burne et al., Clinical Science (1998), Vol. 95, pp. 67-72.					
	"Glomerular Capillary Wall Permeability to Albumin and Horseradish Peroxidase", by Osicka et al., Nephrology 1996, Vol. 2, pp. 199-212.					
	"The Return of Glomerular-Filtered Albumin to the Rat Renal Vein", by Eppel, et al., Kidney International, Vol. 55, (1999), pp. 1861-1870.					
	"Glomerular Charge Selectivity for Anionic and Neutral Horseradish Peroxidase", by Osicka, et al., Kidney International, Vol. 47 (1995), pp. 1630-1637.					
	"Fractional Clearance of High Molecular Weight Proteins in Conscious Rats Using a Continuous Infusion Method", by Burne et al., Kidney International, Vol. 55, (1999), pp. 261-270.					
	"Ramipril and aminoguanidine restore renal lysosomal processing in streptozotocin diabetic rats", T. M. Osicka et al., Diabetologia, (2001), pp. 230-236.					
	"Evaluation of a New Fluorescent Dye Method to Measure Urinary Albumin in Lieu of Urinary Total Protein", Alfredo A. Pegoraro, MD et al., American Journal of Kidney Diseases, Vol. 35, No. 4 (April), 2000, pp. 739-744.					
	Pharmacia Biotech BioDirectory catalog, p. 405.					
	BioRad Life Science Research Products catalog, p. 97.					
EXAMINER			DATE CONSIDERED			

EXAMINER: Initial if referensidered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION				ATTY. DOCKET NO. 62386-043		SERIAL NO. Continuation of Serial No. 09/893,346	
(PTO-1449)				APPLICANT Wayne D. COMPER			
				FILING DATE November 26, 2003		GROUP To be assigned	
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	CITE NO.	Document Number Number-Kind Code ₂ (if known)		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US	4,994,165	02/19/1991	Lee et al.		
		US	4,330,296	5/1982	Jain et al		
		US					
		US					
		US					
		US					
		US					
		US					
		US					
		US					
		US					
		US					
		US					
		US					
		US					
		US					
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	CITE NO.	Foreign Patent Document Country Codes -Number 4 -Kind Codes (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Figures Appear	Translation	
						Yes	No
	A1	DE 44 15 480	11/9/1995	Brucker			
	A1	WO 98/07036	08/13/1997	FROSSMANN		(Japan w/English Abstract)	
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
EXAMINER'S INITIALS	CITE NO.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
		Rohde et al., Electrophoresis, Oct 1998, 19(13):2361-70					
		Jellum et al., J. Chromatogr. B. Biomed. Sci., Feb 1997, 689(1):155					
		Li et al., J Am Soc Mass Spectrom, July 1998, 9(7):701-709					
		Voelter et al., J. Chromatogr. A. May 1998, 807(1):135-49					
		Copies of poster presentation at the European Meeting on Biomarkers of Organ Damage, April 3-7, 2000, Cambridge UK, and abstract accompanying poster					
		Copies of internet pages www.ciphergen.com from May 5, 2000					
		Trevisan et al, Effect of Low-Dose Ramipril on Microalbuminuria, American Journal of Hypertension, Ltd., 1995; 8:876-883					
EXAMINER				DATE CONSIDERED			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.